donepezil has been researched along with Behavior Disorders in 26 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are the two most common types of dementing neurodegenerative disease after Alzheimer's disease (AD)." | 2.46 | Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions. ( Deuschl, G; Förstl, H; Mollenhauer, B; Oertel, W; Storch, A; Trenkwalder, C, 2010) |
| " However, a dose-response study evaluating DON after a controlled cortical impact (CCI) injury in rats did not reveal cognitive benefits." | 1.48 | Systemic administration of donepezil attenuates the efficacy of environmental enrichment on neurobehavioral outcome after experimental traumatic brain injury. ( Bondi, CO; Bou-Abboud, CE; Cheng, JP; Day-Cooney, J; Folweiler, KA; Kline, AE; Leary, JB; Memarzadeh, K; Tehranian-DePasquale, R; Yelleswarapu, NK, 2018) |
| "Treatments in Alzheimer's disease include treatment of cognitive impairment and behavioral manifestations (agitation, depression, anxiety, delusions)." | 1.30 | [Drug therapy strategies in Alzheimer's disease]. ( Lacomblez, L, 1998) |
| "Donepezil has psychotropic properties, and pretreatment behaviors help predict patients' responses to treatment." | 1.30 | The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. ( Barclay, TR; Cummings, JL; Masterman, DM; Mega, MS; O'Connor, SM, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (11.54) | 18.2507 |
| 2000's | 13 (50.00) | 29.6817 |
| 2010's | 9 (34.62) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Dutta, LCB | 1 |
| Sarkar, CP | 1 |
| Andrade, C | 1 |
| Bondi, CO | 1 |
| Yelleswarapu, NK | 1 |
| Day-Cooney, J | 1 |
| Memarzadeh, K | 1 |
| Folweiler, KA | 1 |
| Bou-Abboud, CE | 1 |
| Leary, JB | 1 |
| Cheng, JP | 1 |
| Tehranian-DePasquale, R | 1 |
| Kline, AE | 1 |
| Singh, A | 1 |
| Karasin, J | 1 |
| Madhusoodanan, S | 1 |
| Cumbo, E | 1 |
| Ligori, LD | 1 |
| Hashimoto, K | 1 |
| Matsuda, T | 2 |
| Rodda, J | 1 |
| Morgan, S | 1 |
| Walker, Z | 1 |
| Mollenhauer, B | 1 |
| Förstl, H | 1 |
| Deuschl, G | 1 |
| Storch, A | 1 |
| Oertel, W | 1 |
| Trenkwalder, C | 1 |
| Landau, R | 1 |
| Ago, Y | 1 |
| Koda, K | 1 |
| Ota, Y | 1 |
| Kita, Y | 1 |
| Fukada, A | 1 |
| Takuma, K | 1 |
| Wicklund, S | 1 |
| Wright, M | 1 |
| Sugai, Y | 1 |
| Cummings, JL | 3 |
| McRae, T | 1 |
| Zhang, R | 1 |
| Beier, MT | 1 |
| Campanozzi, MD | 1 |
| Casali, E | 1 |
| Neviani, F | 1 |
| Martini, E | 1 |
| Neri, M | 1 |
| Zarowitz, BJ | 1 |
| Stefanacci, R | 1 |
| Hollenack, K | 1 |
| O'Shea, T | 1 |
| Gruber, J | 1 |
| Tangalos, EG | 1 |
| Omerovic, M | 1 |
| Teipel, SJ | 1 |
| Hampel, T | 1 |
| Belmin, J | 1 |
| Péquignot, R | 1 |
| Konrat, C | 1 |
| Pariel-Madjlessi, S | 1 |
| Wengel, SP | 1 |
| Roccaforte, WH | 1 |
| Burke, WJ | 1 |
| Bayer, BL | 1 |
| McNeilly, DP | 1 |
| Knop, D | 1 |
| Lacomblez, L | 1 |
| Mega, MS | 1 |
| Masterman, DM | 1 |
| O'Connor, SM | 1 |
| Barclay, TR | 1 |
| Dallocchio, C | 1 |
| Buffa, C | 1 |
| Mazzarello, P | 1 |
| Donohue, JA | 1 |
| Brooks, RL | 1 |
| Burt, T | 1 |
| Masanic, CA | 1 |
| Bayley, MT | 1 |
| VanReekum, R | 1 |
| Simard, M | 1 |
| Coulson, BS | 1 |
| Fenner, SG | 1 |
| Almeida, OP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia (FluCOP Trial)[NCT05216614] | Phase 2 | 0 participants (Actual) | Interventional | 2021-12-14 | Withdrawn (stopped due to Unable to obtain investigational product) | ||
| Pilot Examination of Galantamine in the Management of Tic Disorders[NCT00226824] | Phase 4 | 1 participants (Actual) | Interventional | 2005-09-30 | Terminated (stopped due to Unable to recruit subjects into the trial.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for donepezil and Behavior Disorders
| Article | Year |
|---|---|
Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication.
Topics: Animals; Donepezil; Humans; Indans; Mental Disorders; Models, Neurological; Neurotransmitter Agents; | 2015 |
Psychopharmacological Studies in Mice.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Dopamine; | 2016 |
Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Evidence-Based Medicine; Galantamine; | 2009 |
Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions.
Topics: Aged; Brain; Cholinesterase Inhibitors; Cross-Sectional Studies; Dementia; Diagnosis, Differential; | 2010 |
[Spinocerebellar degeneration].
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Donepezil; Female; Humans; Indans; Male; Mental Diso | 2003 |
Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Men | 2007 |
The application of evidence-based principles of care in older persons (issue 5): Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Evidence-Based Med | 2007 |
[Management of Alzheimer disease].
Topics: Aged; Alzheimer Disease; Animals; Antipsychotic Agents; Caregivers; Case Management; Cholinesterase | 2007 |
Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents.
Topics: Affect; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Mental Disord | 2000 |
Successful treatment of behavioural problems in dementia using a cholinesterase inhibitor: the ethical questions.
Topics: Aged; Aged, 80 and over; Australia; Cholinesterase Inhibitors; Donepezil; Ethics; Hallucinations; Hu | 2002 |
4 trials available for donepezil and Behavior Disorders
| Article | Year |
|---|---|
Efficacy of donepezil for the attenuation of memory deficits associated with electroconvulsive therapy.
Topics: Adult; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Electroconvulsive Therapy; Female; | 2020 |
Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Cholinesterase Inhibitors; Dementia | 2014 |
Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders.
Topics: Aged; Cholinesterase Inhibitors; Dementia; Demography; Donepezil; Double-Blind Method; Factor Analys | 2006 |
Open-label study of donepezil in traumatic brain injury.
Topics: Adult; Brain Injuries; Chronic Disease; Donepezil; Humans; Indans; Male; Memory Disorders; Mental Di | 2001 |
12 other studies available for donepezil and Behavior Disorders
| Article | Year |
|---|---|
Systemic administration of donepezil attenuates the efficacy of environmental enrichment on neurobehavioral outcome after experimental traumatic brain injury.
Topics: Analysis of Variance; Animals; Brain Injuries, Traumatic; Cerebral Cortex; Cognition Disorders; Dise | 2018 |
The sound of music: A rare case of auditory Charles Bonnet syndrome in an elderly male.
Topics: Aged; Brief Psychiatric Rating Scale; Charles Bonnet Syndrome; Cholinesterase Inhibitors; Cochlear I | 2019 |
Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions: Evidence is not satisfactory.
Topics: Aged; Brain; Cholinesterase Inhibitors; Cross-Sectional Studies; Dementia; Diagnosis, Differential; | 2011 |
Donepezil, but not galantamine, blocks muscarinic receptor-mediated in vitro and in vivo responses.
Topics: Animals; Animals, Outbred Strains; Cell Line, Tumor; Cerebral Cortex; Cholinesterase Inhibitors; Dis | 2011 |
Donepezil-induced mania.
Topics: Aged; Bipolar Disorder; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Male; Mental D | 2012 |
Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; | 2007 |
[Dementia with Lewy bodies. Clinical improvement under treatment with an acetylcholinesterase inhibitor].
Topics: Aged; Cholinesterase Inhibitors; Donepezil; Hallucinations; Humans; Indans; Lewy Body Disease; Male; | 2007 |
Behavioral complications associated with donepezil.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Mental Disorders; Pip | 1998 |
[Drug therapy strategies in Alzheimer's disease].
Topics: Aggression; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Car | 1998 |
The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Humans; | 1999 |
Combination of donepezil and gabapentin for behavioral disorders in Alzheimer's disease.
Topics: Acetates; Aged; Aged, 80 and over; Alzheimer Disease; Amines; Anticonvulsants; Cholinesterase Inhibi | 2000 |
The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cost of Illness; Donepezil; Humans; Indans; | 2000 |